Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of therapeutic approaches.
Malignant diseases, including haematologic malignancies, are associated with defects in the cell death mechanism. These defects are not only important for the growth advantage of the malignant clone, but when understood can be used for specific therapeutic targeting of malignant cells while sparing normal cells. The promising groups of agents that trigger, directly or indirectly, apoptosis of haematologic cancer cells are reviewed in this article. Some of the agents have recently been approved for therapy, some are under the clinical evaluation in various phases of clinical trials and some are tested under the experimental laboratory conditions.